重组人血小板生成素与白介素-11联合治疗白血病化疗后血小板减少症临床疗效分析  

Analysis of the Clinical Efficacy of Recombinant Human Thrombopoietin and Interleukin-11 in the Treatment of Leukemia Thrombocytopenia after Chemotherapy

作　　者：贺栋 万柏林 邹民[1] HE Dong;WAN Bailin;ZOU Min(Department of Hematology,Ganzhou People's Hospital,Ganzhou,Jiangxi Provice,341000 China)

机构地区：[1]赣州市人民医院血液内科,江西赣州341000

出　　处：《系统医学》2021年第20期49-52,共4页Systems Medicine

基　　金：江西省卫生健康委科技计划(20202081)。

摘　　要：目的探讨重组人血小板生成素与白介素-11联合治疗白血病化疗后血小板减少症临床疗效分析。方法将2019年1月-2020年12月在该院血液科治疗的70例白血病化疗后血小板减少症患者随机分为3组,A组20例使用重组人血小板生成素,B组20例使用白介素-11,C组30例使用重组人血小板生成素与白介素-11联合治疗,对比3组的临床疗效、血常规指标变化、凝血功能指标变化、治疗各指标。结果3组治疗有效率相比,C组100.00%>A组90.00%>B组70.00%,差异有统计学意义(χ^(2)=4.668,P<0.05);3组治疗后WBC、RBC、Hb水平相比差异无统计学意义(P>0.05),C组治疗后PLT水平明显高于A组、B组,差异有统计学意义(P<0.05);3组治疗后凝血酶原时间、部分活化凝血活酶时间、凝血酶时间、纤维蛋白原相比差异无统计学意义(P>0.05);C组持续用药时间、ICU住院时间明显短于A组、B组,血浆、血小板、浓缩红细胞输注量明显低于A组、B组,差异有统计学意义(P<0.05)。结论重组人血小板生成素与白介素-11联合治疗白血病化疗后血小板减少症临床疗效显著,能有效提升血小板水平,缩短治疗时间,减少输血量,且不影响凝血功能,具有积极的临床意义。Objective To investigate the clinical efficacy of recombinant human thrombopoietin and interleukin-11 in the treatment of leukemia thrombocytopenia after chemotherapy.Methods From January 2019 to December 2020,70 leukemia patients with thrombocytopenia after chemotherapy treated in the department of hematology of the hospital were randomly divided into 3 groups,20 patients in group A were treated with recombinant human thrombopoietin,and 20 patients in group B were treated with interleukin-11,30 cases in group C were treated with recombinant human thrombopoietin and interleukin-11 to compare the clinical efficacy,blood routine index changes,coagulation function index changes,and treatment indexes of the 3 groups.Results Compared with the effective rate of treatment in the three groups,group C was 100.00%>group A 90.00%>group B 70.00%,the difference was statistically significant(χ2=4.668,P<0.05);the levels of WBC,RBC,and Hb in the 3 groups were similar after treatment,and the difference was not statistically significant(P>0.05).The PLT level after treatment in group C was significantly higher than that in groups A and B,and the difference was statistically significant(P<0.05);the prothrombin time and partially activated coagulation in the three groups after treatment had no statistically significant difference in active enzyme time,thrombin time,and fibrinogen(P>0.05);the duration of continuous medication and ICU stay in group C was significantly shorter than that of group A and group B,the transfusion volume of plasma,platelets and concentrated red blood cells was significantly lower than that of group A and group B,the difference was statistically significant(P<0.05).Conclusion The combination of recombinant human thrombopoietin and interleukin-11 in the treatment of leukemia thrombocytopenia after chemotherapy has a significant clinical effect.It can effectively increase platelet levels,shorten treatment time,reduce blood transfusion,and does not affect blood coagulation function.It has positive clinical signi

关 键 词：白血病化疗后血小板减少症 重组人血小板生成素 白介素-11 临床疗效 

分 类 号：R773.7[医药卫生—眼科]